Document Detail

The Measels-Mumps-Rubella Vaccination from a health political and economical point of view.
MedLine Citation:
PMID:  21289946     Owner:  NLM     Status:  In-Data-Review    
INTRODUCTION: Measels, Mumps and Rubella (MMR) are highly contagious infectious diseases which may lead to severe complications. These diseases are vaccine-preventable. The present Health Technology Assessment report (report on technological consequences, HTA report) was commissioned by the German Institute of Medical Documentation and Information (DIMDI) and addresses various aspects of the MMR vaccination, the key question being how the MMR immunisation coverage rate can be increased in Germany.
OBJECTIVES: The objectives of this report were to describe the benefits of the MMR vaccination for Germany and to analyse how the desired MMR immunisation coverage of >95% can be achieved.
METHODS: A systematic literature search was performed in 29 literature data bases. Particularly for epidemiological data and information on vaccination programs, this systematic search was supplemented by an extensive hand search, written and oral enquiries, as well as interviews with experts. A total of 200 texts were used to prepare this report.
RESULTS: At 92.5% (as of 2004) based on the whole of Germany, the current immunisation coverage for measles in children is above the weighted EC-15-average of 90.67%. Statements can only be made regarding the probability of illness for measles, as no data is available for mumps and rubella. With 2.8 infections (per 100,000 residents) in 2006, Germany has not achieved the WHO target. Of cases submitted to the laboratory, only 32% were validated by diagnostic laboratory findings and 45% confirmed clinical-epidemiologically. There are only few economic analyses of vaccination programs in Germany. In international publications, mainly measels are validated economically. An analysis of the cost of measles for Germany shows potential cost savings. Unfortunately, no complete economic evaluation (cost-effectiveness, cost-benefit, or cost-utility analyses) for MMR vaccination has been performed for Germany. Analyses conducted in the US and a model calculation for a hypothetical Western-European country show a considerable cost saving potential for society in general as well as for the health care system. INTERVENTIONS TO INCREASE THE IMMUNISATION RATE WERE CATEGORIZED IN THREE MAIN GROUPS ACCORDING TO THEIR GOALS: interventions increasing the demand for vaccinations, those improving access to vaccination services and those aiming at the providers (e.g. physicians) of vaccinations.
DISCUSSION: Various studies concluded that reminders to clients, provided in written, electronic or oral form, are a highly recommendable intervention. Provider based interventions were also strongly advised. DESPITE EFFORTS MADE DURING THE PAST YEARS TO ACHIEVE HERD IMMUNITY IN GERMANY, SOME DEFICITS REMAIN: i. e. there are still ample regional differences between and within German federal states.
CONCLUSIONS: In the authors' opinion, a key point in increasing immunisation coverage is the development of a binding vaccination program for Germany with regionally differentiated immunisation targets. During the development of such a program, special emphasis should be placed on determining responsibilities of the federal government, the Laender and health insurance funds (e. g. in the case of a measles outbreak).
Ingrid Rosian-Schikuta; Barbara Fröschl; Claudia Habl; Heidi Stürzlinger
Related Documents :
21486446 - Rational design of hiv vaccines and microbicides: report of the europrise network annua...
21318606 - Prevention of serious respiratory syncytial virus-related illness. i: disease pathogene...
21419386 - Behaviors and perceptions regarding seasonal and h1n1 influenza vaccination during preg...
21457726 - Contact and communication with healthcare providers regarding influenza vaccination dur...
17464916 - Immunity against infectious diseases: predictive value of self-reported history of vacc...
18849476 - Modeling the effects of strain diversity and mechanisms of strain competition on the po...
Publication Detail:
Type:  Journal Article     Date:  2007-11-28
Journal Detail:
Title:  GMS health technology assessment     Volume:  3     ISSN:  1861-8863     ISO Abbreviation:  GMS Health Technol Assess     Publication Date:  2007  
Date Detail:
Created Date:  2011-02-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101276045     Medline TA:  GMS Health Technol Assess     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  Doc12     Citation Subset:  -    
Gesundheit Österreich GmbH, Geschäftsbereich ÖBIG, Wien, Österreich.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The role of Homocysteine as a predictor for coronary heart disease.
Next Document:  Procedures and Criteria for the regulation of innovative non-medicinal technologies into the benefit...